Trials
6 active
13 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days”In the company’s words, NCT07175220 on ClinicalTrials.gov
- Tested for
- Prostate Cancer (2 trials), Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Follicular Lymphoma, Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Main trialPhase 3
- “This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.”In the company’s words, NCT06122389 on ClinicalTrials.gov
- Other names
- EZH2 Inhibitor
Other drugs for Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up5
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Oct 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2026 | SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma | |
| Phase 2Not yet recruiting | Apr 2027 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | |
| Phase 2Recruiting | Dec 2027 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | |
| Phase 2Recruiting | Oct 2028 | Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects | |
| Phase 2Recruiting | Dec 2028 | A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer | |
| Phase 1/2Recruiting | Dec 2026 | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | |
| Phase 1/2Terminated | 30 Sep 2019 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | |
| Phase 1Unknown | 6 Jan 2022 | A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects | |
| Phase 1Completed | 14 Dec 2022 | Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects | |
| Phase 1Completed | 31 Mar 2023 | Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects | |
| Phase 1Completed | 27 Nov 2023 | A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers | |
| Phase 1Completed | 29 Nov 2023 | Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects | |
| Phase 1Unknown | 14 Feb 2026 | A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026